Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT06522360
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 80
- Registration Number
- NCT06522828
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 30
- Registration Number
- NCT06497530
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Dustin Deming
- Target Recruit Count
- 23
- Registration Number
- NCT06493019
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 29
- Registration Number
- NCT06492759
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Jin Ying
- Target Recruit Count
- 28
- Registration Number
- NCT06483282
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Yunpeng Liu
- Target Recruit Count
- 38
- Registration Number
- NCT06480864
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, China
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 57
- Registration Number
- NCT06477523
- Locations
- 🇨🇳
China West Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Zhangzhou Municipal Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06478264
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.